CVS HEALTH Corp: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 7, 2019 and accepted by EDGAR at Aug 7, 2019, 16:28 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $63.14bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $124.53bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $38.97bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $76.22bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months2019-04-01 to 2019-06-30 | $3.33bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | $6.02bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-04-01 to 2019-06-30 | $772.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2019-01-01 to 2019-06-30 | $1.55bn | us-gaap:InterestExpense |
| Income tax | 3 months2019-04-01 to 2019-06-30 | $660.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-01-01 to 2019-06-30 | $1.17bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | $1.94bn | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | $3.36bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | $1.49 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | $2.58 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | $1.49 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-01-01 to 2019-06-30 | $2.58 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-04-01 to 2019-06-30 | 1,302,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2019-01-01 to 2019-06-30 | 1,302,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | $7.29bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $1.29bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2019-01-01 to 2019-06-30 | $1.31bn | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2019-06-30 | $6.06bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $46.90bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $218.90bn | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $49.38bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $157.31bn | us-gaap:Liabilities |
| Long-term debt | At period end2019-06-30 | $66.94bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-06-30 | $3.89bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2019-06-30 | $446.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2019-06-30 | $61.28bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000064803-19-000039. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.